Chief Investment Officer

Nigel Pitchford

Contact Nigel


Nigel is the Chief Investment Officer and is responsible for Innovation’s investment activities. He joined Innovations in January 2012. He was previously a Partner at DFJ Esprit, and prior to that spent 12 years at 3i, becoming a Partner in 2006, and ultimately leading the venture team's healthcare activities across Europe and the US. Nigel is a board member of Veryan Medical, Abzena, Oxular and Nexeon.

During his venture career he has been responsible for leading investment rounds into Domantis (sold to GSK for $454m), Apatech (sold to Baxter for $330m), Arakis (sold to Sosei Pharma for $187m), Horizon Discovery (AIM: HZD) and Oxford Immunotec (NASDAQ: OXFD), amongst others. He has also served on the boards of EUSA Pharma (sold to Jazz for $700m) and HBI (sold to Meda AB for $282m).

Nigel studied chemistry at the University of Oxford, before completing a PhD at the University of Durham. His research activities included rational drug design and saw him join the Cambridge Crystallographic Data Centre (CCDC) in 1994, where he spent two years working on new product design and projects for pharmaceutical company clients. He completed an MBA at Warwick Business School, before joining 3i in 1997.

Contact details

Email Nigel

Personal Assistant

Name: Lisa Flynn
Telephone: 020 3053 8841
Email Lisa